Compare Natera Inc. Common Stock (NTRA) vs Snap Inc (SNAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Snap Inc — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while Snap Inc trades at $6.05 (market cap $10.98B). The key difference: Natera Inc. Common Stock is far larger — about 5.2× Snap Inc's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Snap Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Snap Inc for 68 Days on average.
| NTRA | SNAP | |
|---|---|---|
Market Cap | $57.03B | $10.98B |
Volume | 1,131,157 | 53,140,165 |
Sector | Health | Media |
52-Week High | $425.64 | $9.09 |
52-Week Low | $179.42 | $3.93 |
Typical Hold Time | 0 Days | 68 Days |
Enterprise Value | $56.18B | $12.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Snap Inc. (SNAP) trades at $6.10, down 6.73% over 24 hours, with technical indicators showing a bullish trend despite overbought RSI signals. The company reported revenue growth to $5.93B in 2025, though net losses persist at -$460M, with improving margins. Recent news highlights AI and AR developments, including SPECS glasses partnerships with NVIDIA and Salesforce, driving investor optimism amid regulatory pressures.
The outlook remains cautious; while analyst consensus is a $7.91 price target with 38% buy ratings, risks include sustained losses, high debt, and competitive threats. Upside hinges on monetizing AI innovations and achieving profitability, but volatility from sentiment shifts poses near-term challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →
